As of Feb 09
| -0.13 / -0.33%|
The 27 analysts offering 12-month price forecasts for GlaxoSmithKline have a median target of 44.62, with a high estimate of 52.53 and a low estimate of 36.48. The median estimate represents a +13.42% increase from the last price of 39.34.
The current consensus among 30 polled investment analysts is to Hold stock in GlaxoSmithKline. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.